Antivascular Endothelial Growth Factor-A Treatment: New Perspectives for High-Risk Plaque Stabilization

Journal of the American College of Cardiology

Volumn 50, Issue 2, 2007, Pages 186-

  Toutouzas, Konstantinos ^a   Karabelas, John ^a   Vaina, Sophia ^a   Stefanadis, Christodoulos ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ENDOTHELIAL CELL GROWTH FACTOR;

ANGIOGENESIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; GENE TRANSFER; HUMAN; HYPERTENSION; INTIMA; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM; ULTRASOUND;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CORONARY ARTERIOSCLEROSIS; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 34347242807     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.05.001     Document Type: Letter

References (5)

1. Ylä-Herttuala S., Rissanen T., Vajanto I., and Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49 (2007) 1015-1026
2. Moreno P.R., Purushothaman K.R., Sirol M., Levy A.P., and Fuster V. Neovascularization in human atherosclerosis. Circulation 113 (2006) 2245-2252
3. Stefanadis C., Toutouzas K., Stefanadi E., Kolodgie F., Virmani R., and Kipshidze N. First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: angiographic results in a rabbit atheromatic model. Hellenic J Cardiol 47 (2006) 7-10
4. Toutouzas K., Stefanadi E., Kolodgie F., et al. Mid-term clinical follow-up results of first-in-man implantation of bevacizumab-eluting stent: a new approach for inhibiting plaque neovascularization (abstr). Eur Heart J 27 (2006) 3442
5. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 (2005) 8033-8040